Fractyl Labs ropes in $44M in series D funding for balloon ablation device for Type 2 diabetes

The Fractyl Laboratories team (Courtesy of Fractyl Laboratories)

Fractyl Labs reeled in $44 million in series D funding to spur development of its balloon ablation device for Type 2 diabetes.

An “undisclosed new investor” led the round, joining other new investors such as GV, True Ventures and the IDO Fund, Fractyl said in a statement. Returning investors including General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital Management, Emergent Medical Partners and Deerfield Management Company also chipped in funds.

Fractyl plans to use the funds to develop its water-filled balloon device, Revita DMR. The cash will be used for an ongoing clinical trial of the device.


Lipid-based Formulations for Early Stage Clinical Trials

Liquid-filled capsule technology has a proven record for addressing complex API formulation challenges, but also offers a simple and effective pathway to the clinic. Register now to learn more about lipid-based formulations.

The Waltham, MA-based company has already charted progress with Revita. In 2015, Fractyl showed in a study of 39 patients that its technology helped reduce hemoglobin A1C levels (HbA1c) up to six months after the procedure.

The device, which is already CE marked, works by burning the lining of the duodenum, a part of the small intestine that produces hormones that regulate food intake and blood sugar, to improve blood glucose levels in patients. The process, called duodenal mucosal resurfacing, could be used to treat individuals with diabetes who aren’t a good fit for or who opt out of weight-loss surgery.

Investors seem sold on Revita’s potential. In September 2014, Fractyl locked down $40 million in series C funding on the heels of promising clinical trial results for its device. Type 2 diabetes cost the U.S. healthcare system $245 million in 2012, Fractyl pointed out at the time, and the company’s Revita system can be performed endoscopically in a clinical setting without much pain or discomfort—a potential selling point to payers.

"More than 50 new drugs have been approved to manage Type 2 diabetes, yet too many patients still remain unable to control their disease and are at risk for serious complications from their disease. At Fractyl we have developed a minimally invasive, catheter-based procedural therapy that we believe can help reverse Type 2 diabetes,” Fractyl CEO Harith Rajagopalan said in a statement.

Suggested Articles

Invitae aims to expand its genetic counseling reach through the $50 million acquisition of Clear Genetics, developers of digital chatbot software.

Gilead presented studies at AASLD showing how noninvasive testing and machine learning could improve diagnostics and drug development for NASH.

HDL unveiled data showing its treatment reduced reduced coronary artery damage in patients with a genetic disorder that causes high cholesterol.